Company logo
Sector: Healthcare
Industry: Diagnostics & Research

Myriad Genetics Inc

Ticker - MYGN
Country: US
Exchange: NASDAQ

Monitor Performance using this Dynamic, Always Current, Periodic Table of Investments

Data:

Time:

Alignment:

About Myriad Genetics Inc

  • Company Overview: Myriad Genetics, Inc. (MYGN) is a molecular diagnostic company that specializes in the development and commercialization of genetic tests. The company aims to improve healthcare outcomes through the application of genetic information in clinical decision-making.
  • Core Business Segments:
    • Genomic Testing: Myriad offers a range of genetic tests aimed at predicting disease risk, guiding treatment decisions, and informing patient management for various diseases. Key test categories include cancer risk assessment and genetic testing for hereditary cancer, pharmacogenomics, and reproductive health.
    • Oncology: Under its oncology division, Myriad focuses on hereditary cancer tests, such as BRCA1 and BRCA2 testing, which help assess an individual's risk for certain cancers. Additional tests in this segment include myRisk, which analyzes multiple genes related to cancer susceptibility.
    • Women’s Health: Myriad is a pioneer in reproductive health, particularly through its Preceda test, which provides non-invasive prenatal testing services. This division also includes services for conditions related to fertility and pregnancy complications.
  • Genomic Testing: Myriad offers a range of genetic tests aimed at predicting disease risk, guiding treatment decisions, and informing patient management for various diseases. Key test categories include cancer risk assessment and genetic testing for hereditary cancer, pharmacogenomics, and reproductive health.
  • Oncology: Under its oncology division, Myriad focuses on hereditary cancer tests, such as BRCA1 and BRCA2 testing, which help assess an individual's risk for certain cancers. Additional tests in this segment include myRisk, which analyzes multiple genes related to cancer susceptibility.
  • Women’s Health: Myriad is a pioneer in reproductive health, particularly through its Preceda test, which provides non-invasive prenatal testing services. This division also includes services for conditions related to fertility and pregnancy complications.
  • Competitive Position:
    • Market Leadership: Myriad Genetics is recognized as a leader in the genetic testing market, particularly for hereditary cancer assessment. Their brand is well-respected, and they have established partnerships with numerous healthcare providers.
    • Innovation and R&D: The company invests significantly in research and development to expand its testing portfolio and improve existing products, maintaining its competitive edge in a rapidly evolving market.
    • Regulatory Compliance: Successful partnerships and market penetration hinge upon Myriad’s ability to navigate the complex regulatory landscape surrounding genetic testing, which can pose challenges but also opportunities for reputable firms.
  • Market Leadership: Myriad Genetics is recognized as a leader in the genetic testing market, particularly for hereditary cancer assessment. Their brand is well-respected, and they have established partnerships with numerous healthcare providers.
  • Innovation and R&D: The company invests significantly in research and development to expand its testing portfolio and improve existing products, maintaining its competitive edge in a rapidly evolving market.
  • Regulatory Compliance: Successful partnerships and market penetration hinge upon Myriad’s ability to navigate the complex regulatory landscape surrounding genetic testing, which can pose challenges but also opportunities for reputable firms.
  • Financial Performance:
    • Revenue Streams: Myriad's revenues come primarily from the sales of its genetic tests. As the demand for personalized medicine continues to grow, the company is well-positioned to benefit financially from its established testing offerings.
    • Profitability Challenges: Despite a strong product portfolio, Myriad has faced challenges related to reimbursement rates from insurers and competition from lower-cost entrants in the genetic testing market, which may impact profitability.
    • Cash Flow Considerations: Monitoring cash flow will be crucial for investors, especially as the company scales its operations and continues to invest in new product development while also addressing operational efficiencies.
  • Revenue Streams: Myriad's revenues come primarily from the sales of its genetic tests. As the demand for personalized medicine continues to grow, the company is well-positioned to benefit financially from its established testing offerings.
  • Profitability Challenges: Despite a strong product portfolio, Myriad has faced challenges related to reimbursement rates from insurers and competition from lower-cost entrants in the genetic testing market, which may impact profitability.
  • Cash Flow Considerations: Monitoring cash flow will be crucial for investors, especially as the company scales its operations and continues to invest in new product development while also addressing operational efficiencies.
  • Market Context:
    • Competitive Landscape: The molecular diagnostics market is competitive, with other players offering genetic testing solutions. Myriad faces competition from companies like Invitae, Natera, and Guardant Health, which can erode market share.
    • Trends in Healthcare: The increasing emphasis on precision medicine and personalized healthcare presents both opportunities and challenges. As healthcare providers seek better patient management solutions, Myriad's genetic tests may become more integral in clinical practices.
    • Regulatory Environment: Changes in regulation and healthcare policy can impact reimbursement models and access to genetic testing, which may affect Myriad's market positioning and profitability.
  • Competitive Landscape: The molecular diagnostics market is competitive, with other players offering genetic testing solutions. Myriad faces competition from companies like Invitae, Natera, and Guardant Health, which can erode market share.
  • Trends in Healthcare: The increasing emphasis on precision medicine and personalized healthcare presents both opportunities and challenges. As healthcare providers seek better patient management solutions, Myriad's genetic tests may become more integral in clinical practices.
  • Regulatory Environment: Changes in regulation and healthcare policy can impact reimbursement models and access to genetic testing, which may affect Myriad's market positioning and profitability.
    • SWOT ANALYSIS

    SWOT Analysis is a strategic planning tool used to identify and understand the key factors that can impact a business or project. What are the key factors for gaining a competitive market share advantage? Also, what potential threats should we be wary of during our Process?

    STRENGTHS

    • MYGN has a strong portfolio of oncology-focused products that cater to a growing market.
    • It possesses a robust intellectual property portfolio, giving it competitive protection in the biotechnology space.
    • MYGN's established relationships with healthcare providers enhance its market reach and improve patient access to its products.

    WEAKNESSES

    • Dependence on a limited number of products can lead to revenue volatility if those products face competition.
    • High research and development costs can strain financial resources, particularly in a competitive environment.
    • Potential regulatory hurdles may impact the speed at which new products are brought to market.

    OPPORTUNITIES

    • Expanding into emerging markets presents significant growth potential for MYGN's product offerings.
    • Strategic partnerships and collaborations could enhance R&D capabilities and innovative capability.
    • The increasing demand for personalized medicine provides a lucrative avenue for new product development.

    THREATS

    • Intense competition from both established biotech firms and startups poses a threat to market share.
    • Healthcare policy changes can adversely affect pricing and reimbursement strategies for MYGN's products.
    • Market volatility and economic downturns could affect investment in biotech research, impacting MYGN's growth potential.

    Please enjoy this free portfolio visualization and monitoring tool. Click Install from the address bar for easy and fast future access.

    Paid accounts can visualize any portfolio or watchlist in this performance visualization… plus a million other cool things — including daily data, sharing custom tables for the assets you care about, industry-leading portfolio backtesting, and full portfolio strategy analytics. Both individual and professional versions are supported.

    Performance Disclosure

    This portfolio is hypothetical.


    This is a historical simulation of the portfolio performance an investor would have obtained had you invested in the same selections at the beginning of the simulation. This report provides information on how the portfolio holdings would have changed and would have performed for a certain period. We have strived to reduce or eliminate potential biases in the process to provide the most accurate assessment of the performance prospects of the strategy. However, it may not be possible for any historical simulation to completely ensure it is free of all biases.


    Please see
    Gold Standard for Portfolio Backtesting and
    Seven Deadly Sins of Portfolio Backtesting
    for a more complete understanding of risks and biases when backtesting portfolio strategies.


    Backtested strategies also run the risk of cherry picking. Cherry Picking is when the author of the backtest has created many variations and is presenting one of the variations that is more favorable. This research was not produced in whole or in part by cherry picking.


    This simulation is based on an account with tax exempt or tax deferred growth. Taxable accounts will have to pay the appropriate taxes for dividends, interest, and capital gains, which will decrease the performance depicted.


    This simulation is not based on actual trading accounts or account composites which may or may not exist for this strategy and may be materially different including worse than the performance illustrated above. Past performance is not necessarily indicative of future performance. Performance results including risk and diversification measures are not guaranteed to persist in the future.


    This historical performance simulation has been adjusted to reflect estimated management fees.


    The suitability of this portfolio strategy requires that you have thoughtfully and accurately completed your investor objectives from your accounts’ Investment Policy Statement. Login


    Diversification strategies alone cannot assure a successful investment outcome. Strategies offering greater diversification also fail to guarantee any reduction in loss of capital.


    Your ability to follow this investment strategy is a risk. Investors often dispose of successful strategies at inopportune times thus turning potentially profitable strategies into losses.


    Portfolio data is taken from sources believed to be accurate, however, there is no warranty or guarantee as to the accuracy or completeness of data and statistical calculations thereupon. Portfolio ThinkTank does not furnish investment advice without an investment advisory agreement.


    The period of time selected for analysis may have a significant bearing on the relative attractiveness of the strategy and the strategy versus another portfolio or benchmark. The author of the strategy controls the default period of time used to analyze performance and from there, users may select any desired period of time from the menu. In general, longer periods, greater diversification and lower concentrations of holdings result in more credible, more persistent performance evaluations.


    If this strategy includes predictions created by our deep learning neural net, there are additional risks that portfolio strategies and their backtested performance may have risks of having the data be overfit and consequently perform better in the backtest than it may in real account performance. We manage these risks regularly and in many ways. However, due to the attention mechanisms in a deep learning neural network, it may not be possible to eliminate these risks. To learn if your portfolio strategy is built using predictions from a neural network or to better understand our mitigation policies, we invite you to start a conversation: hello@gravityinvestments.com